OS DESAFIOS DA IMUNOTERAPIA DE RNA MENSAGEIRO NO TRATAMENTO DO CÂNCER
DOI:
https://doi.org/10.56238/levv16n54-035Palavras-chave:
Vacinas Contra o Câncer, Imunoterapia de Mrna, Antígenos Específicos do Tumor, Imunomoduladores Tumorais, Vacina de MrnaResumo
Dado a recorrente demanda por eficientes formas de tratar o câncer e suas adversidades, este estudo foi desenvolvido na finalidade de agregar conhecimentos para colaborar com uma das alternativas mais inovadoras e eficazes no combate a complexidade e resistência das células tumorais, a imunoterapia com utilização de mRNA. Para o mesmo, foram empregados banco de dados de 2015 a 2025 sobre a uso de mRNA no desenvolvimento de vacinas para câncer, bem como o mecanismo, especificações e implicações, ressaltando os principais desafios e resultados no desempenho das pesquisas. Logo, esta revisão visa elucidar a eficácia da terapia, demostrando ensaios clínicos promissores em diversas frentes oncológicas e destacando a relevância dessa tecnologia na capacidade de modular a expressão gênica de forma altamente seletiva frente a proliferação descontrolada das células cancerígenas, a resistência a tratamentos e a evasão imunológica. Por fim, este estudo, por meio de acervo bibliográfico, integra com informações na busca por soluções, e medidas mais recentes para tratamento dos diferentes tipos de cânceres que acometem a humanidade.
Downloads
Referências
AL FAYEZ, Nojoud et al. Recent advancement in mRNA vaccine development and applications. Pharmaceutics, [S.l.], v. 15, n. 7, p. 1972, 2023.
CARNEIRO, Benedito A. et al. First‑in‑human study of MEDI1191 (mRNA encoding IL‑12) plus durvalumab in patients (pts) with advanced solid tumors [abstract CT183]. Cancer Research, v. 82, n. 12 Suppl., p. CT183–CT183, 2022.
CUI, Jia-Wen et al. Tumor immunotherapy resistance: Revealing the mechanism of PD-1/PD-L1-mediated tumor immune escape. Biomedicine & Pharmacotherapy, v. 171, p. 116203, 2024..
DI MEO, Francisco et al. Mapping the cancer surface proteome in search of target antigens for immunotherapy. Molecular Therapy, 32(9), 2892-2904, 2024.
FU, Qiang et al. mRNA vaccines in the context of cancer treatment: from concept to application. Journal of Translational Medicine, [S.l.], v. 22, n. 1, p. 402, 2025.
FU, Yong; TANG, Renhong; ZHAO, Xiaofeng. Engineering cytokines for cancer immunotherapy: a systematic review. Frontiers in Immunology, v. 14, 2023, artigo 1218082.
GAO, Yu et al. mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends. Biomarker Research, v. 12, art. n. 93, 2024.
GULLEY, James L. et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, v37, n13, p1051–1061; 2019.
HE, Qing et al. mRNA cancer vaccines: Advances, trends and challenges. Acta Pharmaceutica Sinica B, [S.l.], v. 12, n. 7, p. 2969‑2989; 2022.
HONG, Yichen et al. mRNA delivery in cancer immunotherapy. Acta Pharmaceutica Sinica B, v. 13, n. 4, p. 1348-1357, 2023.
HOU, Xucheng et al. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, v. 6, n. 12, p. 1078–1094, 2021.
JOYCE, Johanna A.; FEARON, D.T. T cell exclusion, immune privilege, and the tumor microenvironment. Science, v348, e6230, p74-80; 2015.
KENNEDY, Lucy B.; SALAMA, April K. S. A review of cancer immunotherapy toxicity. CA: a cancer journal for clinicians, v70. e2, p86–104; 2020.
KONG, B. et al. mRNA: A promising platform for cancer immunotherapy. Advanced Drug Delivery Reviews, v. 199, art. 114993, 2023.
KONG, Shijia et al. Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy. Cancer Letters, v. 611, p. 217432, 2024.
KOWALSKI, Piotr S. et al. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Molecular Therapy, v27, n4, p710–728; 2019.
LAM, Jenny K. W. et al. siRNA Versus miRNA as Therapeutics for Gene Silencing. Molecular Therapy Nucleic Acids, v4, e252; 2015.
LI, Jiangping et al. The screening, identification, design and clinical application of tumour‑specific neoantigens for TCR‑T cells. Molecular Cancer, [S. l.], v. 22, art. 141, 2023.
LI, Hang et al. Cancer mRNA vaccines: Clinical application progress and challenges. Cancer Letters, v. 625/626, p. 217752, 2025.
LI, Minghui et al. mRNA delivery in cancer immunotherapy: lipid nanoparticles and beyond. Acta Pharmaceutica Sinica B, v. 13, n. 7, p. 2632–2653, 2023.
LIU, Rui et al. PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy. Cell Insight, v. 3, n. 2, p. 100146, 2024.
LIU, Zaoqu et al. Engineering neoantigen vaccines to improve cancer personalized immunotherapy. International Journal of Biological Sciences, 18(15), 5607-5623, 2025.
LV, Zhen; DAI, Yuheng. mRNA vaccines and SiRNAs targeting cancer immunotherapy: challenges and opportunities. Discover Oncology v16, n1265; 2025.
MAGEE, Diane E. et al. Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials. Annals of oncology: official journal of the European Society for Medical Oncology, v31. e1, p50–60; 2020.
MEHTA, Apoorva et al. A Review of PD‑1 Inhibitors, T‑VEC, mRNA Vaccines, and Other Emerging Therapies for Advanced Melanoma. Journal of Clinical Medicine, v. 14, n. 4, art. 1200, 2025.
OTT, Patrick A.; WU, Catherine J. Cancer vaccines: steering T cells down the right path to eradicate tumors. Cancer Discovery, v9, n4, p476–481; 2019.
PARDI, Norbert et al. mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery v17, p261–279; 2018..
PARK, Seohyun et al. Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics. Cancers, v17, e16, n2628; 2025.
PATEL, Chirag H.; POWELL, Jonathan D. Immune Cell Metabolism and Immuno‑Oncology. Annual Review of Cancer Biology, v. 7, p. 93‑110, 2023.
RAHMAN, Md Ataur et al. A Comprehensive Review of Nanoparticle-Based Drug Delivery for Modulating PI3K/AKT/mTOR-Mediated Autophagy in Cancer. International Journal of Molecular Sciences, v26, e5, n1868; 2025.
SALAZAR, Ulisse et al. Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives. Immuno-Oncology Technology, v. 28, 2025.
SAHIN, Ugur et aI. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, v. 547, p. 222–226, 2017..
SETHNA, Zachary et al. RNA neoantigen vaccines prime long‑lived CD8⁺ T cells in pancreatic cancer. Nature, v639, p1042–1051; 2025.
SHEN, You-Min. Advances of mRNA vaccines in genitourinary cancers. Reviews on Cancer, v. 1880, p. 189427, 2025.
SILVA, Estela Vieira de Souza et al. Elucidando a imunovigilância e imunoedição tumoral: uma revisão abrangente. Ciência Animal Brasileira, Goiânia, v22, e68544; 2021.
WEBER, Jeffrey S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. The Lancet, v. 403, n. 10443, p. 847–857, 2024.
WU, Da‑Wei et al. Personalized neoantigen cancer vaccines: current progression, challenges and a bright future. Clinical and Experimental Medicine, v. 24, art. 229, 2024.
YANG, Wenqian et al. Polymer‑Based mRNA Delivery Strategies for Advanced Therapies. Advances in Healthcare Materials, v. 12, n. 15, e2202688, 2023.
ZHANG, A. et al. mRNA vaccine in gastrointestinal tumors: Immunomodulatory effects and immunotherapy. BioMed Pharmacother., v. 166, p. 115361, 2023.
ZHANG, Zheng et al. Recent advances in mRNA delivery for cancer therapy. Molecular Cancer, v22, p14; 2023.
ZHAO, Yue et al. Cancer Vaccines: Antigen Selection Strategy. Vaccines (Basel), v. 9, n. 2, art. 85, 2021.
